Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. - Wikidata - awgldk - TriplyDB

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

http://www.wikidata.org/entity/Q36142693

about

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles Prostate cancer screening in Brazil: should it be done or not?The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Early detection of prostate cancer: AUA Guideline.Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort Prostate-specific antigen screening in prostate cancer: perspectives on the evidence Recommendations on screening for prostate cancer with the prostate-specific antigen test.Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring Serum markers in prostate cancer detection Prostate-specific antigen-based screening: controversy and guidelines Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.Identification of plasma protein profiles associated with risk groups of prostate cancer patients Predicting prostate cancer many years before diagnosis: how and why?Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.Screening for prostate cancer: early detection or overdetection?Overdiagnosis of prostate cancer.Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men Prostate cancer: is it time to expand the research focus to early-life exposures?Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.Risk-based prostate cancer screening.Chemoprevention of prostate cancer: an updated view.Prostate-specific antigen concentration in young men: new estimates and review of the literature.American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.The Kallikrein Panel for prostate cancer screening: its economic impact.The Melbourne Consensus Statement on the early detection of prostate cancer.Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection.Young-age prostate cancer.The Effects of Beginning Population Based PSA Screening at Age 40.KLK-targeted Therapies for Prostate Cancer.The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years

P2860

Q26865810-63C31964-C718-4892-AE92-20F48B2D562D Q28068688-A1E157C9-0749-4D8F-9BFD-7B5F00D3124F Q30239973-49F52D5A-D8BE-4976-9E7E-CAB255AC45C7 Q33585860-AE505759-ED96-4CB6-A8B1-32545AAD1F1C Q33608474-964C01ED-4445-44C9-983B-DF0EBD1EFDC7 Q33643656-23D92DE7-05C3-4A26-BB4B-6B34105F20E3 Q33820579-9009FA2E-C4B6-4247-909B-0F6B9AC05117 Q34354430-7C5279DB-E11D-449C-BE0F-F0ABBD384DA6 Q34435885-3D16A569-201A-4181-9989-0C900130EC00 Q34468372-20175698-01BD-4D6F-AC1D-57F51E4F8960 Q34677912-8D19BD07-81DF-47C5-927D-54F1157BC1CF Q34810177-810E4AFF-85EF-46BF-AE79-75AE277071FB Q35042519-0CCC16D6-5276-4D42-946A-398687489664 Q35211931-E3DB8940-E344-4BA8-BFBC-D1C375E43B86 Q35718345-4E9CDCAA-F0B7-4D84-AA05-5A8A919AC15E Q35881136-B7CD6DE2-ACA7-41CA-80B6-0A7056B42378 Q35940183-B7CCD92F-BAA1-471B-A0E0-28E4B9EE2013 Q36026045-BCE73376-6C78-4588-8476-FDB737AA52AA Q36051375-9D72BCE9-B308-4CEC-89CA-D4332A4FBA8E Q36145417-2E4E6B2C-EFFF-4F4A-BADE-3B9C260179EE Q36152421-FF348B69-224D-418F-B3D6-584B98DF9BC4 Q36520508-7B0ED5AB-902B-400C-984D-4C0ABD33E2FD Q36590875-388A50AA-CB52-4E09-A936-574493986671 Q37103771-951B60E0-7D23-4F06-BE2F-6D359D216BE0 Q37300931-458FC19C-F392-4237-A7BE-D5B2317E0C43 Q37619482-48B905D3-9B4D-4D88-B51C-333F65A5C5AE Q37656490-2DB062A9-3991-46F7-BE09-6782456007D6 Q37671113-7EC561F5-FAF9-4802-80A4-14B562E2FC96 Q37963657-08E5DBA2-E2C5-4E70-9D78-456BE22B2E67 Q37975188-81FC7F3E-472F-47A9-982F-D8153C42C923 Q38002516-FCAF841D-DC6B-4281-817A-48BC711451CB Q38127277-BCDC9CCC-E8B6-497D-B75C-A1FC74C5DAAB Q38156099-6953C46C-B08B-4B1C-9083-D309E25D8506 Q38160903-75F599E0-897F-4306-98EC-E1A7FD48B3EC Q38268839-D074A6A8-C540-4E0B-AA5B-268C5D1AE1F2 Q38383052-B5C98C17-B879-40BE-A4E3-4548175AD860 Q38402732-3A12B117-21CE-493A-AF9E-030D5FAA3DF0 Q38607830-1D8B5FEE-4EA8-4FB9-B100-3DD51EB128E3 Q38967486-5C2BEFFB-CE69-46EE-AC69-0B7B39FEA96E Q41975608-BD314D37-D021-40C9-B69B-B5C6FEE20C91

P2860

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

http://www.wikidata.org/entity/Q36142693

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Prediction of significant pros ...... c antigen at or before age 50.

@ast

Prediction of significant pros ...... c antigen at or before age 50.

@en

type

label

Prediction of significant pros ...... c antigen at or before age 50.

@ast

Prediction of significant pros ...... c antigen at or before age 50.

@en

prefLabel

Prediction of significant pros ...... c antigen at or before age 50.

@ast

Prediction of significant pros ...... c antigen at or before age 50.

@en

P1433

Q36142693-426F388F-681E-4B2C-BCD9-2AE66B9E68C9

P1476

Q36142693-1E3462AF-500D-4743-AA8C-25742D61AE94

P2093

Q36142693-0C0A74EA-E21C-4B44-A03C-410068E4A4BB

Q36142693-18F58A19-6815-4F43-991A-9D4432A03CD4

Q36142693-60E6E320-60F4-4690-98BB-AB72CBA1987A

Q36142693-80FA98F6-B3BC-4A40-A1E0-081D8DA183F8

Q36142693-C8160B56-4B2E-4023-97F5-5303104AF46E

Q36142693-F8615F03-D43E-4530-8DDA-4B1C8D18C1AF

Q36142693-F9436574-BD8F-4D99-94DE-EF0EB181234F

P2860

Q36142693-0B9D2CFE-9910-444C-913A-AFC4F3C84A32

Q36142693-0EC718CB-212D-481C-8B53-FD9F1D609347

Q36142693-131B3572-6897-4624-AA15-56CC52705B3A

Q36142693-1A32106D-09DD-40A8-8086-C70591048CD9

Q36142693-26753BBB-CCB6-46DC-A8EA-69C302CEC90F

Q36142693-294E4C2A-691E-492D-B79F-3F5AB37F1601

Q36142693-2A5455F8-84F4-4EAF-AAF9-ADC59E337C06

Q36142693-2C3BE74D-6064-4790-87CD-F445F8066DDD

Q36142693-2E43A1A9-9DF6-4C77-8370-2376CB77630C

Q36142693-3104B6E8-8D7C-42EF-A580-2935BFB18E73

P304

Q36142693-3313AE9B-B64C-4377-995A-0FC87A559512

P31

Q36142693-C738332D-01D7-46C1-BA8D-02CDBE0FD43C

P356

Q36142693-8A101A32-89DE-4154-98A4-929E73E3BFC2

P407

Q36142693-7D9215CA-B83B-44EB-8137-3F6C45223F93

P433

Q36142693-3430EC8D-CEE2-4BCF-AC3B-C8360F9D7D16

P478

Q36142693-060642DF-31B9-456B-AE63-E6567D31F7B7

P50

Q36142693-6BF6A38E-13D1-400F-85C6-CE14035F564C

Q36142693-D0C62CBE-41F6-463A-9DF5-D330665864A7

Q36142693-E07A8CCD-B004-4D09-B76D-2CCCFD063AB5

P577

Q36142693-D75D667C-24EF-47A5-A2DB-F293A3EEF31E

P5875

Q36142693-009B3176-1486-42AC-A2EC-B05828A90A4A

P698

Q36142693-C00A7D0A-6DA8-4D97-9696-D51BBF52D12B

P932

Q36142693-9C4DED8F-B576-4BB4-A6A1-486CE3755174

P356

P1433

P1476

Prediction of significant pros ...... ic antigen at or before age 50

@en

P2093

Anders Dahlin

http://www.w3.org/2001/XMLSchema#string

Anders S Bjartell

http://www.w3.org/2001/XMLSchema#string

Angel M Cronin

http://www.w3.org/2001/XMLSchema#string

James A Eastham

http://www.w3.org/2001/XMLSchema#string

Jonas Manjer

http://www.w3.org/2001/XMLSchema#string

Peter M Nilsson

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Multiple newly identified loci associated with prostate cancer susceptibility

Screening and prostate-cancer mortality in a randomized European study

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Validity of a population-based cancer register in Sweden--an assessment of data reproducibility in the South-East Region Prostate Cancer Register.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.

Probabilistic analysis of global performances of diagnostic tests: interpreting the Lorenz curve-based summary measures.

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.

SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?

P304

1210-1219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25568

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

P577

2010-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227771059

http://www.w3.org/2001/XMLSchema#string

P698

20960520

http://www.w3.org/2001/XMLSchema#string

P932

3412541

http://www.w3.org/2001/XMLSchema#string